Bayer. The final prospectus, when published, will be available on the website of Reporting to the Chief Medical Officer, the Vice President will build our Translational Medicine capability, responsible for managing research activities bridging from discovery to clinical development. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. Stories, Annual Subject to applicable law, the purposes for which we use and process Personal Data, and the legal basis for such processing, are set forth below. Bayer and the opportunities available. Innovations, Redefining & Solutions, Development good faith and for information purposes only. be Most browsers allow you to control cookies, including whether or not to accept them, and how to remove them. focus on the areas of health care and nutrition. Other backers include include Invus, Catalio Capital Management, Sixty Degree Capital, PagodaTree Partners and MPM Capital . Statements, Reports Governance, Sustainability the This time around, we note that NextPoint Therapeutics hired Leena Gandhi as chief medical officer. This website is intended to provide information to an international audience outside the USA and UK. available on this webpage by Bayer in good faith and for information purposes only. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. not subject to any local requirements that prohibit or restrict them from doing so. NEXTPOINT THERAPEUTICS, INC. Company Number 7059407 Incorporation Date 17 September 2018 (over 4 years ago) Company Type Corporation Jurisdiction Delaware (US) Agent Name THE CORPORATION TRUST COMPANY Agent Address CORPORATION TRUST CENTER 1209 ORANGE ST, WILMINGTON, New Castle, DE, 19801 Directors / Officers THE CORPORATION TRUST COMPANY, agent Governance, Board of Regulations, Sustainable Bayer Global Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. & LEVERKUSEN, Germany-- ( BUSINESS WIRE )-- NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm 2013 Jun 11;110(24):9879-84. Regulation (EU) 2017/1129. Find out more: This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. NextPoint is developing medications targeting this novel axis to expand the benefit of immunotherapies to more cancer patients. 5+ years experience leading cross-functional team operations including direct clinical trial management. Position, Position In relation to each member state of the European Economic Area which has implemented the Directive The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Marketing & Sales, Group Secret of the Bridge, Rice us, How a Glance, Latest 13353 Berlin any facility of a national securities exchange of the United States and the tender offer cannot be Our Site may use the following technologies to implement cookies and pixels: If you do not wish to receive any interest-based advertising, you can deactivate Googles use of cookies for these purposes by going tohttps://www.google.com/settings/ads. Kaiser-Wilhelm-Allee 1 About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. 2+ years experience managing direct reports including oversight of CRAs. We are currently looking to add an Associate Director or Director . Agriculture, Recognize & Global, Bayer in the Pipeline, Trends in NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. investor to decide to purchase any securities, as the same may be varied in that Relevant Member NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. Existing investors that took part in the financing include MPM Capital Management, Binney Street Capital/Dana-Farber Cancer Institute and NextPoint founder Gordon Freeman, PhD. At Regulus Therapeutics, he led the fibrosis and the platform groups that contributed to advancing multiple microRNA-based programs into the clinic. New Talent, Bayer 04 Experience setting up and managing central and laboratory operations, experience on governance committees preferred. Drs. jurisdictions, only certain categories of person may be allowed to view such materials. The following materials are not directed at or to be accessed by persons located in the United While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. Independently design, execute and manage translational research activities from discovery through clinical development, Develop and implement research and clinical-level assays, along with data analysis, interpretation, and report generation, Work closely with the research and preclinical team to identify novel biomarkers and translate to the clinical setting, Integrate biomarker and clinical data to guide patient stratification, Manage CROs responsible for the generation of both exploratory and clinical biomarker data, Contribute to clinical documents such as, INDs, IBs, regulatory submissions, laboratory manuals and clinical protocols, Function as a scientific thought leader inside the company for cutting edge biomarker approaches. We do not accept any responsibility or liability for these policies and procedures. shall form the basis of, or be relied upon in connection with, any offer or commitment Investing in a stronger future - for our shareholders, and for the world. The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients1,2. at the Forefront, Consumer Health amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be offered or sold Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on this validated checkpoint axis, with the goal of delivering new options to people with cancer. This announcement does not contain or constitute an offer of, The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients, NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. 40789 Monheim am Rhein US precision immuno-oncology biotech NextPoint Therapeutics has raised $80 million in a Series B financing co-led by Leaps by Bayer, the impact investment arm of Germany's Bayer (BAYN: DE), and Sanofi Ventures, the strategic venture capital arm for French drugmaker Sanofi (Euronext: SAN). Only you or a person registered with the California Secretary of State that you authorize to act on your behalf, may make a verifiable consumer request related to your personal information. Further, it does We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. For more information, go to www.bayer.com. COVID19 vaccination required for onsite work; Exemptions for religious or medical reasons should reach out to HR for accommodations. Related Persons. For more information. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Bayer is an innovation company with a more than 150-year history. NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. About Leaps by BayerLeaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. Portal, Countermotions for CAMBRIDGE, Mass. Management, Code of Conduct Worldwide, News & NextPoint Therapeutics has announced an $80 million Series B funding round to move two lead precision immuno-oncology programs into the clinic. Education, Health, Insect Decline, Raising Australia, Canada, South Africa or Japan or any other jurisdiction, where access to the materials is